Physician profile
Yi Li
NPI 1730525999
$25,863.14
in general payments reported to CMS, 2019-2025
40 companies · $4,699 in 2025
The $4,699 reported for 2025 was more than what 85% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $4,294 · 2021: $3,858 · 2022: $3,833 · 2023: $3,786 · 2024: $5,054 · 2025: $4,699.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,419.12 |
| Education | $119.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,799.45 | 2019-2025 | |
| Amgen INC. | $4,725.25 | 2020-2025 | Enbrel, Otezla, Krystexxa |
| Janssen Biotech, INC. | $2,986.75 | 2019-2025 | Tremfya, Simponi Aria, Stelara |
| Horizon Therapeutics Plc | $2,301.72 | 2020-2023 | Krystexxa |
| Novartis Pharmaceuticals Corporation | $1,794.29 | 2020-2025 | |
| Glaxosmithkline, LLC. | $1,730.44 | 2020-2025 | Benlysta |
| Astrazeneca Pharmaceuticals LP | $1,239.28 | 2021-2025 | Saphnelo, Tezspire, Farxiga |
| Lilly USA, LLC | $885.31 | 2019-2025 | Taltz, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $686.67 | 2019-2025 | Orencia |
| Ani Pharmaceuticals, INC. | $565.38 | 2023-2025 | Purified Cortrophin Gel |
| Genentech USA, INC. | $542.52 | 2019-2025 | Rituxan, Actemra, Gazyva |
| Ucb, INC. | $517.90 | 2020-2025 | Bimzelx, Cimzia |
| Aurinia Pharma U.S., INC. | $450.65 | 2021-2025 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $383.73 | 2020-2025 | Acthar |
| Janssen Scientific Affairs, LLC | $382.00 | 2021-2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $262.15 | 2019-2025 | |
| Kiniksa Pharmaceuticals International, Plc | $192.52 | 2024 | Arcalyst |
| Radius Health, INC. | $170.24 | 2020-2025 | Tymlos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.40 | 2023-2025 | Spevigo, Cyltezo, Ofev |
| Fresenius Kabi USA, LLC | $156.67 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Genzyme Corporation | $139.65 | 2020-2025 | |
| Alexion Pharmaceuticals, INC. | $122.38 | 2019-2025 | Strensiq, Ultomiris |
| Medtronic, INC. | $97.56 | 2025 | Closurefast |
| Biocon Biologics INC | $71.01 | 2024 | Hulio |
| Tersera Therapeutics LLC | $66.50 | 2024 | Quzyttir |
| Scilex Pharmaceuticals INC. | $60.37 | 2024-2025 | |
| Mallinckrodt Enterprises LLC | $54.71 | 2019 | |
| Celltrion USA INC. | $53.41 | 2025 | Vegzelma |
| Organon LLC | $40.44 | 2021-2025 | Hadlima, Renflexis |
| Tonix Medicines, INC. | $27.10 | 2025 | Tonmya |
| Ultragenyx Pharmaceutical INC. | $23.32 | 2020 | |
| Invivyd INC | $22.19 | 2025 | Pemgarda |
| Biohaven Pharmaceuticals, INC. | $21.78 | 2021 | |
| Octapharma USA, INC. | $19.78 | 2025 | Octagam Immune Globulin (Human) |
| Pacira Therapeutics, INC. | $19.67 | 2021 | |
| Celgene Corporation | $19.03 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $18.97 | 2023 | Arcalyst |
| Arbor Pharmaceuticals, INC. | $18.09 | 2021 | |
| Fidia Pharma USA INC. | $16.18 | 2024 | Hymovis, Triluron, Hyalgan |
| Teva Pharmaceuticals USA, INC. | $13.68 | 2024 | Truxima |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yi Li listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.